Semaglutide
The drug that made the category, and is now trying to hold its lane.
Semaglutide has a decade of published evidence and is still the most-prescribed agent in the class. The desk follows the long-term data, the cardiovascular story, the oral formulation, and the real-world experience of patients who are now years in.
This Week's Feature
Hand-picked by the desk.
Semaglutide's Second Act Is About the Heart
SELECT showed a 20% reduction in major cardiovascular events. Cardiologists are rewriting secondary-prevention playbooks in real time. The obesity angle may end up being the smaller story.
Read the feature →